Subscribe To

Price Alert Latest News Economic Calendar News

SKYE / Skye Bioscience selects NextPharma as phase 2 contract drug manufacturer

Skye Bioscience Inc (OTCQB:SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, said it has selected NextPharma as its contract manufacturing organization (CMO) for its phase 2 clinical trial material. NextPharma is a European pharmaceutical contract development and manufacturing organization that supplies products globally from its nine sites. Read More

Demo Live Account See Partner Details

Content Topics

SKYE

Bioscience

Selects

Nextpharma

Phase

Contract

Drug

Manufacturer

Stock

Posted: Jul 21 2022, 07:50

Author Name: Proactive Investors

SKYE News

By Proactive Investors
February 2, 2023

Skye Bioscience hires ophthalmic-focused CRO for Phase 2a US trial of glaucoma and hypertension treatment

Skye Bioscience Inc (OTCQB:SKYE) has entered into an agreement with Lexitas Pharma Services Inc, a full-service ophthalmic-focused contract research o

By Proactive Investors
January 31, 2023

Skye Bioscience gets positive safety review of SBI-100 OE after phase 1 first cohort

Skye Bioscience Inc (OTCQB:SKYE) said it has received a positive recommendation following a pre-specified data review by the safety review committee (

By Proactive Investors
December 20, 2022

Skye Bioscience receives US FDA authorization of Investigational New Drug Application for SBI-100 OE

Skye Bioscience Inc (OTCQB:SKYE) said the US Food and Drug Administration (FDA) has authorized it to proceed with the Investigational New Drug (IND)

By Proactive Investors
December 16, 2022

Skye Bioscience says dosing completed of SBI-100 Ophthalmic Emulsion in the first cohort of the single ascending dose part of its Phase 1 study

Skye Bioscience Inc (OTCQB:SKYE) said it has completed dosing of SBI-100 Ophthalmic Emulsion (OE) in the first cohort of healthy participants in the s

By Proactive Investors
December 13, 2022

Skye Bioscience appoints Dr Chris Twitty as chief scientific officer

Skye Bioscience Inc (OTCQB:SKYE) said it has hired Dr Chris Twitty as the company's first chief scientific officer (CSO). With over 25 years of life

By Newsfile Corp
November 22, 2022

Skye Bioscience to Present at RHK 2022 Disruptive Growth Conference

San Diego, California--(Newsfile Corp. - November 22, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company

By Proactive Investors
November 16, 2022

Skye Bioscience recruits patients for first cohort in trial to treat glaucoma with ophthalmic drug

Skye Bioscience Inc (OTCQB:SKYE) said it has started screening for its first-in-human Phase 1 trial of SBI-100 Ophthalmic Emulsion (SBI-100 OE), a pr

By Proactive Investors
November 11, 2022

Skye Bioscience concludes merger with Emerald Health Therapeutics and unveils goals for 2022 and 2023

Skye Bioscience Inc (OTCQB:SKYE) announced that it has concluded the merger with Emerald Health Therapeutics after both companies' shareholders voted

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.